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Melanoma is one of the most aggressive types of
human cancers, and the mechanisms underlying
melanoma invasive phenotype are not completely
understood. Here, we report that expression of
guanosine monophosphate reductase (GMPR), an
enzyme involved in de novo biosynthesis of purine
nucleotides, was downregulated in the invasive
stages of human melanoma. Loss- and gain-of-func-
tion experiments revealed that GMPRdownregulates
the amounts of several GTP-bound (active) Rho-
GTPases and suppresses the ability of melanoma
cells to form invadopodia, degrade extracellular
matrix, invade in vitro, and grow as tumor xenografts
in vivo. Mechanistically, we demonstrated that
GMPR partially depletes intracellular GTP pools.
Pharmacological inhibition of de novo GTP biosyn-
thesis suppressed whereas addition of exogenous
guanosine increased invasion of melanoma cells as
well as cells from other cancer types. Our data iden-
tify GMPR as a melanoma invasion suppressor and
establish a link between guanosine metabolism and
Rho-GTPase-dependent melanoma cell invasion.
INTRODUCTION
Acquisition of the invasive phenotype, a critical event for mela-
noma metastasis, is initiated in primary cutaneous melanoma.
Although various characteristics of primary melanoma such as
Breslow thickness determine clinical prognosis, the mecha-
nisms underlying this invasive process are not completely under-
stood (Balch et al., 2009; Haass and Smalley, 2009; Leong et al.,
2012). One of the major prerequisites for the invasion of malig-Cnant cells is the ability to degrade the extracellular matrix
(ECM) and the underlying basement membrane in order to
escape the primary site of growth (Friedl and Alexander, 2011;
Lu et al., 2011) Many factors can influence these properties,
including formation of invadopodia, specialized subcellular
actin-rich structures that recruit proteolytic enzymes to the areas
of cell-ECM contact (Caldieri et al., 2009, Ridley, 2011). In many
types of cancer, including melanoma, invasion and the ability to
form invadopodia have been strongly associatedwith the activity
of small GTPases, in particular those of the Rho-GTPase family
(Buccione et al., 2009, Struckhoff et al., 2011).
Rho-GTPases (including the most-studied members RHOA,
RHOC,RAC1,andCDC42) are small 21 kDaproteins that regulate
the formation of actin structures and processes associated with
these structures, including adhesion,migration, and invasion (Ta-
kai et al., 2001; Kaibuchi et al., 1999; Ridley, 2006). In their active,
GTP-boundstate, thesesmallGTPases interactwithdownstream
effectors to initiate and/or propagate signaling events. Hydrolysis
of GTP to GDP renders the GTPases inactive (Takai et al., 2001;
Van Aelst and D’Souza-Schorey, 1997). Although small GTPases
have an intrinsic GTP hydrolyzing activity, the spontaneous reac-
tions of hydrolysis and subsequent GDP to GTP nucleotide
exchange are extremely slow. These processes are regulated
by GTPase-activating proteins (GAPs) that enhance intrinsic
GTPase activity, guanine nucleotide exchange factors (GEFs)
that promote exchange of GDP for GTP (Schmidt and Hall,
2002;Moon and Zheng, 2003), and the guanine nucleotide disso-
ciation inhibitors (GDIs) that maintain GTPase in inactive form in
the cytoplasm (Moon and Zheng, 2003). Activities of GAPs,
GEFs, and GDIs are in turn regulated bymultiple signal cascades
(Moon and Zheng, 2003; Van Aelst and D’Souza-Schorey, 1997).
The question ofwhether tumor cells possess the intrinsic ability to
regulate the invasionandactivity of theaboveGTPasesbymanip-
ulating intracellular GTP pools has never been addressed.
Neoplastic cells, including melanoma, are highly dependent
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(Dang, 2012; Tong et al., 2009), and enzymes involved in these
pathways are substantially upregulated in cancer cells (Liu
et al., 2008; Mannava et al., 2008, 2012, 2013). De novo biosyn-
thesis of guanosine monophosphate (GMP) requires several
enzymes, including inositol monophosphate dehydrogenase 1
and 2 (IMPDH1 and IMPDH2) that convert inositol monophos-
phate (IMP) into xanthosine monophosphate (XMP) (Collart and
Huberman, 1988) and guanosine monophosphate synthetase
(GMPS) that converts XMP into GMP (Zalkin, 1985) (Figure 1A).
A reverse reaction, catalyzed by guanosine monophosphate
reductase (GMPR) (Spector et al., 1979), converts GMP to IMP
to fuel back into both the AMP and GMP synthesis pathways
(Figure 1A). IMPDH2 has been functionally linked to cell prolifer-
ation and carcinogenesis and its levels were suppressed in
arrested cells (Jayaram et al., 1999; Mannava et al., 2008; Nagai
et al., 1992). The functional role of GMPR in the biology of cancer
cells has never been addressed.
The current work presents evidence for a previously unrecog-
nized ability of cancer cells to increase the activity of Rho-
GTPases, leading to the formation of invadopodia and invasion
via upregulation of GTP pools, and identifies GMPR as a poten-
tial tumor suppressor that inhibits this regulatory pathway in
tumor cells. In addition, using human samples representative
of invasive cutaneous and metastatic melanoma, we validated
our findings in a clinical setting.
RESULTS
Expression Levels of GMPR and IMPDH2 Are Altered in
Metastatic Melanoma Cells
To investigate the role of intracellular GTP metabolism in tumor
progression of melanocytic cells, we compared protein levels
of the enzymes involved in de novo GTP biosynthesis (Figure 1A)
in a panel of three independently isolated populations of normal
human melanocytes (NHM) and nine arbitrarily chosen human
metastatic melanoma cell lines. All populations of melanocytes
expressed readily detectable levels of GMPR, in striking contrast
with cells from the melanoma panel where GMPR expression
was undetectable in all but one melanoma cell line (Figure 1B).
A strong suppression of GMPR expression in themajority of met-
astatic melanoma cell lines was also confirmed at the mRNA
level using quantitative RT-PCR (Figure S1A). Previously, we
have demonstrated that levels of IMPDH2 were upregulated in
metastatic melanoma cells (Mannava et al., 2008). We confirmed
these findings here as IMPDH2 expression levels were higher in
all studiedmelanoma cells compared to NHM (Figure 1B). GMPS
expression levels showed little variation across all examined cell
lines and populations (Figure 1B). These data suggest that theFigure 1. GMPR Is Downregulated at Invasive Stages of Melanoma
(A) Schematic representation of the de novo purine biosynthesis and salvage
respectively. *IMPDH 1/2 are rate-limiting enzymes and MPA targets.
(B) Total cellular extracts from independently isolated populations of normal hu
western blotting with the indicated antibodies.
(C) Expression of GMPR and IMPDH2 in thin, thick primary melanomas andmelan
median, first quartile, and third quartile are shown in the ‘‘box’’ with outlying sam
(IQR) times 1.5 added to the first and third quartiles. The number of patient samp
(D) Representative IHC images for GMPR and IMPDH2 from the data presented
See also Figure S1.
Cexpression of GMPR and IMPDH2 may be altered in the course
of melanoma progression.
GMPR Expression Is Associated with the Invasive
Phenotype in Clinical Settings
To authenticate the specificity of GMPR and IMPDH2 antibodies
used in Figure 1B in an immunohistochemistry (IHC) setting, cell
pellets from two populations of NHM and cells from several
melanoma lines were formalin-fixed, paraffin-embedded, and
stained using the above antibodies the same way as the patient
melanoma specimens (see Supplemental Experimental Proce-
dures), followed by scoring for the intensity of staining. Expres-
sion levels of IMPDH2 or GMPR in NHM versus melanoma cells,
determined by western blotting, correlated well with the expres-
sion levels identified by IHC staining (Figure S1B).
To validate the expression pattern of GMPR and IMPDH2
observed in cultured cells, we analyzed their protein expression
levels by IHC in 249 human melanoma specimens. For the
purpose of comparison, all patients were divided into one of
three cohorts: primary cutaneous thin melanoma (Breslow thick-
ness % 2 mm), primary cutaneous thick melanoma (Breslow
thickness > 2 mm), and metastatic melanoma, consisting of
36, 46, and 167 patients, respectively (see Supplemental Exper-
imental Procedures). Melanoma specimens were scored for
intensity of staining and percentage of stained cells (see Exper-
imental Procedures). An IHC index was calculated as a product
of these parameters and used to semicategorically assess
GMPR and IMPDH2 expression levels (Figures 1C and 1D). A
statistically significant correlation was identified between
GMPR expression and Breslow thickness for the primary cuta-
neous cohorts. The cohort of thin melanomas showed higher
GMPR expression than the cohort of thick melanomas (Fig-
ure 1C). Importantly, and in accordance with the findings in the
primary cutaneous cohorts, GMPR expression was significantly
lower in the metastatic melanoma cohort compared to the thick
melanoma cohort (Figure 1C). Unlike GMPR, expression levels of
IMPDH2 did not differ between thin and thick melanomas or
between the cutaneous and metastatic cohorts (Figure 1C),
although IMPDH2 expression was higher in metastatic mela-
nomas compared to thin melanomas. No correlation existed
betweenGMPRor IMPDH2 expression and outcome (metastatic
disease) within the thin or thick melanoma cohort (Table S1),
suggesting that the above observations are directly related to
the invasive process and not to other confounding factors. Addi-
tionally, no correlation was found between theGMPR or IMPDH2
expression and patient age for all cohorts or anatomical location
in the primary melanoma cohorts (head and neck, limbs, trunk)
(see Table S1). These data demonstrate that expression ofpathway. Enzymes and their products are shown by ovals and open boxes,
man melanocytes (NHM) and indicated melanoma cell lines were probed in
omametastases. The box plots represent the distribution of the IHC index. The
ples represented by points. The dashed lines represent the interquartile range
les (n) is indicated for each cohort.
in (C).
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Figure 2. GMPR Enzymatic Activity Is Required for Suppression of Invasion
(A) Indicated melanoma cells were transduced with empty lentiviral vector or vector expressing human GMPR cDNA. Four days after transduction, total protein
extracts from transduced cells and from normal human melanocytes were probed in western blotting with the indicated antibodies.
(B and C) Cells were also tested for proliferation (B) or invasion (C).
(D) Melanoma cells were transduced with empty lentiviral vector, vector expressing wild-type GMPR, or putative catalytic null mutant of GMPR (GMPRC186A).
(E) Four days after transduction, total protein extracts from infected cells were probed in western blotting with the indicated antibodies and assayed for
proliferation or invasion.
(F) Intracellular GTP amounts were measured by HPLC in SK-Mel-103 cells expressing empty vector or GMPR. Normalized amounts of the nucleotides are
shown.
(legend continued on next page)
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GMPR is suppressed in invasive cutaneous and metastatic
melanoma.
GMPR Enzymatic Activity Affects Melanoma Cell
Invasion
Invasion is one of the major features distinguishing thick and thin
cutaneous melanomas (Balch et al., 2009). Our finding that
GMPR levels are decreased in thick melanomas implys that
GMPRmay negatively regulate invasion. To test this hypothesis,
we restored GMPR levels in highly invasive human melanoma
cells (SK-Mel-103 and SK-Mel-147) via lentivirus-based trans-
duction of human GMPR cDNA. By adjusting the lentiviral titer,
we were able to achieve physiological levels of exogenous
GMPR comparable to the endogenous GMPR levels found in
NHM (Figure 2A). Control and GMPR-expressing cells displayed
similar proliferative rates, as determined by incorporation of the
deoxyuridine analog EdU (Figure 2B). Nonetheless, melanoma
cells ectopically expressing GMPR demonstrated a substantial
impairment in the ability to invade through Matrigel matrix
(Figure 2C).
To investigate whether GMPR enzymatic activity is required
for the suppression of melanoma cells invasion, we generated
a putatively catalytically inactive mutant of human GMPR by
substituting cysteine with alanine at position 186 (GMPRC186A).
This mutation has been previously shown to abolish catalytic
activity of GMPR2, a conserved homolog of GMPR, in vitro (Li
et al., 2006). Overexpression of GMPRC186A at levels comparable
to overexpression of wild-type GMPR (Figure 2D) did not affect
invasion (Figure 2E), suggesting that enzymatic activity of
GMPR is essential for its ability to inhibit invasion of melanoma
cells.
Although it has never been shown in cells, by converting GMP
to IMP, GMPR may negatively regulate cellular GTP pools (Fig-
ure 1A). To determine if this was the case, wemeasured amounts
of ribonucleoside triphosphates in SK-Mel-103 cells expressing
vector or GMPR cDNA. We found that GTP levels were repro-
ducibly lower by 24% in cells expressing GMPR compared to
control cells (Figure 2F). Levels of ATP remained virtually un-
changed (95.8% ± 0.3% of controls), whereas the amounts of
CTP and UTP were slightly elevated in GMPR-expressing cells
(by 9.57% ± 0.5% and 17.7% ± 0.3%, respectively).
Recently, Arozarena et al. reported that depletion of cyclic
GMP (cGMP) via upregulation of cGMP-specific phosphodies-
terase PDE5A affects melanoma cell invasion (Arozarena et al.,
2011). Therefore, we measured the levels of cGMP in control
and GMPR-expressing SK-Mel-103 cells and found that GMPR
did not affect cGMP amounts (Figure S2A).
To confirm that depletion of GTP pools is critical for GMPR-
dependent inhibition of melanoma cell invasion, control and
GMPR-overexpressing cells were tested for invasion and prolif-
eration in media supplemented with 100 mM of exogenous gua-
nosine (a concentration commonly used to reverse intracellular
GTP depletion in mammalian cells; Gu et al., 2003; Laliberte´(G) Cells described in (A) were treated or not with 100 mM of guanosine for 24 hr
(H) Human breast carcinoma MDA-MB-231 and human colon carcinoma HCT11
nosine were assayed for invasion as described above. Cells expressing the indic
All panels show representative experiments. Data represent mean ± SEM. *p < 0
Cet al., 1998). Addition of guanosine did not increase proliferation
rates of GMPR-expressing melanoma cells but substantially
increased their invasion (Figure 2G). The invasion of control cells
incubated with guanosine was also increased (Figure 2G).
Importantly, manipulations of GMPR expression levels or the
addition of exogenous guanosine, produced similar results in
human breast carcinoma cells MDA-MB-231 cells and human
colon carcinoma cells HCT116 (Figures 2H and S2B).
All together, these results suggest that GMPR and GTP pools
play an important role in invasion of different types of tumor cells.
GMPR Affects Formation of Invadopodia and Matrix
Degradation
Invasion has been in many cases directly linked to their ability of
tumor cells to form invadopodia, actin-richmembrane structures
that are capable of recruiting proteolytic activities to induce local-
ized degradation of the ECM (Caldieri et al., 2009; Nu¨rnberg et al.,
2011; Ridley, 2011). To detect active invadopodia, melanoma
cells were plated on fluorescein isothiocyanate (FITC)-conju-
gated gelatin and active invadopodia were visualized using
microscopy by matching immunofluorescent actin puncta with
areas of gelatin degradation (Figure 3A) as described earlier
(Branch et al., 2012; Alexander et al., 2008). This methodology
allowedus to determine the number of cellswith active invadopo-
dia, the number of active invadopodia per cell, and the area of
gelatin degradation per cell (Figure 3B). In agreement with the
data described above, ectopic expression ofGMPRsubstantially
affected the ability of melanoma cells to form invadopodia and to
degrade gelatin, whereas the addition of 100 mM guanosine
completely alleviated the negative effects of GMPR (Figure 3A).
Taken together, these data characterize GMPR as a negative
regulator of invadopodia formation and matrix degradation,
therefore providing amechanistic explanation to the hindered in-
vasion potential of melanoma cells overexpressing GMPR.
GMPR Affects Melanoma Cell Tumorigenicity
Invasion as a mean for release of space constraints has been
shown to contribute to the growth of subcutaneous tumor cell
xenografts in immunocompromised mice (Hotary et al., 2003).
Therefore, we were interested in testing whether GMPR would
affect cell tumorigenicity as well. To this end, SK-Mel-103 and
SK-Mel-147 cells transduced with empty lentiviral vector or vec-
tor encoding GMPR cDNA were inoculated subcutaneously in
both flanks of athymic nude mice (ten mice per condition). We
found that ectopic expression of GMPR in SK-Mel-103 and
SK-Mel-147 cells significantly increased latency of tumors
(calculated as the time period from inoculation date to the
appearance of tumors at 50% of inoculated sites) compared to
controls (9 days versus 5 days in SK-Mel-103 cells and
13 days versus 7 days in SK-Mel-147 cells) (Figure 3C). GMPR
overexpression also suppressed growth of tumor xenografts
derived from SK-Mel-103 and SK-Mel-147 cells (Figure 3D).
Additionally, fluorescence microscopy showed that tumorfollowed by assessment of invasion indices and incorporation of EdU.
6 cell expressing or not the indicated constructs and treated or not with gua-
ated constructs were tested in an immunoblot for GMPR expression.
.05; **p < 0.001 by Student’s t test. See also Figure S2.
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xenografts originated from GMPR-overexpressing SK-Mel-103
cells grew in the subcutaneous tissue (panniculus adiposus)
without invading the muscular layer (panniculus carnosus) that
separates dermis and subcutaneous adipose tissue (Figure S3A).
On the other hand, control xenografts showed amore aggressive
pattern of growth with invasion through the muscular layer into
the epidermis (Figure S3A). To verify that the xenografts retained
GMPR expression, GMPR levels were assessed in a separate
experiment in transduced SK-Mel-103 cells before inoculation
and in individual tumors 11 and 15 days after inoculation. As
shown in Figure S3B, GMPR overexpression was retained
throughout the course of the experiments. Additionally, we eval-
uated colony-forming potential of vector- andGMPR-expressing
cells in semisolid agarose. Agarose cannot be metabolized by
mammalian cells, and therefore the ability of a cell to degrade
ECM should not influence its ability to form colonies in this assay.
Indeed, no significant difference in the number or size of colonies
was identified between vector- andGMPR-expressing cells (Fig-
ure 3E), suggesting that the xenograft latency was not due to a
change in anchorage-independent growth. To ascertain that
ectopic expression of GMPR was not suppressed in the course
of the experiments, GMPR levels were measured in cells
cultured for 12 days on a plate or in semisolid conditions. As
shown in Figure S3C, the GMPR levels were retained throughout
the experimental time frame.
Suppression of GMPR Promotes Invasion and
Tumorigenicity of Melanoma Cells
Among tested melanoma cells lines, only SK-Mel-28 cells
expressed measurable amounts of GMPR (Figures 1B and
S1A). These cells demonstrated proliferation rates similar to
those of SK-Mel-103 and SK-Mel-147 cells (Figure 4A), but their
invasion index was several-fold lower (Figure 4B). Thus, SK-Mel-
28 cells represent a convenient model to study the effects of
GMPR depletion on melanoma cell invasion. SK-Mel-28 cells
were transduced in parallel with two GMPR small hairpin RNAs
(shRNAs) or with control shRNA (Figure 4C). The transduced
populations were tested for proliferation (Figure 4D), Matrigel in-
vasion (Figure 4E), and combined gelatin degradation assay
(Figures 4F and 4G). In good agreement with the above observa-
tions, we found that depletion of GMPR resulted in the increase
of all studied parameters of cell invasion (Figures 4E–4G). More-
over, supplementation of cultured media of control SK-Mel-28
cells with guanosine led to an elevation in intracellular GTP levels
(in agreement with previous studies; Hines et al., 2010; Nouri
et al., 2011) (Figure S4A) and increased invasion similarly to
GMPR-depleted cells (Figures 4E–4G).Figure 3. GMPR Affects Invasion-Associated Phenotypes of Melanom
(A) Melanoma cells were transduced with the indicated constructs. Four days aft
stained with rhodamine-conjugated phalloidin. Where indicated, cells were grow
plating on the gelatin.
(B) The area of degradationwas determined by ImageJ software. The number of ce
invadopodia were counted as phalloidin-positive puncta overlapping with the are
(C) Indicated melanoma cells expressing vector or GMPR were inoculated in bot
when they reached at least 2 mm in one dimension.
(D) Tumor xenografts formed by melanoma cells described in (C) were measured
(E) Cells described in (C) were grown in semisolid agarose for 12 days.
All panels describe representative experiments. Data represent mean ± SEM. ‘‘±
CTo test whether GMPR depletion would increase tumor forma-
tion, SK-Mel-28 cells transduced with control- or two GMPR
shRNAs were subjected to the tumorigenicity assays described
in the previous section. We found that GMPR depletion substan-
tially decreased tumor latency of SK-Mel-28-derived tumors,
identified as the time period from the inoculation date to the
appearance of tumors at 25% of inoculated sites (9 and 7 days
for cells expressing GMPR shRNA 1 and 2, respectively, versus
13 days for control shRNA cells) (Figure 5A). Moreover, suppres-
sion of GMPR levels detected before tumor cell inoculation was
retained in the tumor xenografts at the time of their appearance
(Figure S5A). On the contrary, GMPR depletion did not affect
ability of SK-Mel-28 cells to form colonies in semisolid agarose
(Figure 5B) as the amounts of GMPR were depleted throughout
the course of the experiments (Figure S5B).
Additionally, GTP levels were analyzed in NMH, SK-Mel-103,
and SK-Mel-28 cells. Melanoma cells were found to possess
increased GTP amounts compared to NHM (33% and 47%,
respectively; Figure S4B). Accordingly, GMPR depletion in
NHM resulted in increased GTP levels (9.6%–10.4%) and
elevated motility (Figures S4C–S4E).
Altogether, these data demonstrate that depletion of GMPR
promotes cellular phenotypes associated with invasion and up-
regulates melanoma cell tumorigenicity.
GMPR Differentially Regulates Activity of Several Rho-
Family GTPases
We hypothesized that GMPR suppresses the ability of mela-
noma cells to form invadopodia, degrade collagen, and subse-
quently invade ECM via inhibition of the activity of one or several
Rho-family GTPases, which have been previously reported to
play a pivotal role in these processes (Buccione et al., 2009;
Struckhoff et al., 2011). We also hypothesized that such inhibi-
tion occurs via subtle GMPR-induced depletion of intracellular
GTP, which is required for the activity of these GTPases.
To test these hypotheses, we assessed the activity of RAC1,
CDC42, RHOA, and RHOC, key regulators of tumor cell invasion,
in control and GMPR-expressing SK-Mel-103 cells using a
commercially available GTPase pull-down assay. Following
precipitation, total GTPase (in the input) andGTP-boundGTPase
(in the precipitate) were detected by western blotting with anti-
bodies specific to individual GTPase. As shown in Figure 6A,
overexpression of GMPR did not affect total amounts of RAC1,
CDC42, RHOA, or RHOC; however, GMPR-expressing cells
contained reproducibly lower levels of GTP-bound RAC1,
RHOA, and RHOC, but not GTP-bound CDC42 (Figures 6A
and 6H).a Cells
er transduction, cells were plated on FITC- gelatin for 16 hr and then fixed and
n in media supplemented with 100 mM guanosine for 24 hr prior to and after
lls with gelatin degradation was determined by counting at least 50 cells. Active
a of gelatin degradation.
h flanks of nude mice (n = number of inoculation sites). Tumors were recorded
at indicated time points. The results are expressed as mean volume ± SEM.
’’ represents SD. *p < 0.05 by Student’s t test. See also Figure S3.
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A B Figure 5. Suppression of GMPR Increases
Melanoma Cell Tumorigenicity
(A) SK-Mel-28 cells expressing indicated shRNAs
were inoculated into flanks of nude mice (n = number
of inoculation sites). Tumors were recorded when
they reached at least 2 mm in one dimension.
(B) Cells described in (A) were grown in semisolid
agarose for 12 days.
All panels describe representative experiments. ‘‘±’’
represents SD. *p < 0.05 by Student’s t test. See also
Figure S5.To independently verify that subtle depletion of intracellular
GTP pools may indeed affect the activity of some but not other
RHO-GTPases, we utilized mycophenolic acid (MPA), a chemi-
cal inhibitor of IMPDH1 and IMPDH2 (Ransom, 1995; Sievers
et al., 1997) often used for the depletion of GTP pools (Franchetti
and Grifantini, 1999; Yalowitz and Jayaram, 2000). By titrating
MPA, we were able to determine experimental conditions
(0.4 mM of MPA for 24 hr) at which invasion of SK-Mel-103 cells
was suppressed without any effects on their proliferation (Fig-
ure 6B); i.e., similarly to GMPR overexpression. Importantly,
such treatment resulted in depletion of GTP (Figure 6C), compa-
rable to those achieved by overexpression of GMPR (Figure 2F).
Furthermore, like GMPR-overexpressing cells, the amounts of
GTP-bound RAC1, RHOA, and RHOC, but not CDC42, were
lower in cells treated with MPA (Figures 6D and 6H). It is note-
worthy that in each experiment, the amounts of GTP-bound
RAC1 were depleted to a higher degree than GTP-bound
RHOA or RHOC.
We then asked whether depletion of GMPRwould reciprocally
lead to increased amounts of GTP-bound small GTPases. To
address this question, we performed pull-down experiments in
SK-Mel-28 cells expressing control or GMPR-specific shRNA1
or shRNA2. Our results showed that levels of GTP-bound
RAC1, RHOA, and RHOC, but not CDC42, were higher in cells
depleted of GMPR compared to cells expressing control shRNA
(Figures 6E and 6H). Moreover, the addition of exogenous
guanosine to uninfected SK-Mel-28 cells also increased the
amounts of GTP-bound RAC1, RHOA, and RHOC, but not
CDC42 (i.e., comparably to GMPR depletion) (Figures 6F and
6H). Furthermore, like GMPR depletion, treatment with guano-
sine increased the relative amounts of GTP-bound RAC1 more
than GTP-bound RHOA or RHOC. To determine whether
GMPR acts upstream of studied Rho-GTPases, we tested
whether the manipulation of GMPR expression in SK-Mel-103
and SK-Mel-28 cells would affect the activation status of otherFigure 4. Suppression of GMPR Promotes Invasion of Melanoma Cells
(A and B) SK-Mel-28, SK-Mel-103, and SK-Mel-147 cells were tested for prolifer
(C) Total protein extracts of SK-Mel-28 cells expressing control shRNA (Cl), GMP
indicated antibodies.
(D and E) Incorporation of EdU (D) and invasion index (E) were determined for in
(F) Cells described in (A) were plated on FITC gelatin for 16 hr and then fixed and sta
in media supplemented with 100 mM guanosine for 24 hr prior to and after platin
(G) The area of degradation was determined by ImageJ software. The number o
Active invadopodia were counted as phalloidin-positive puncta overlapping with
All panels describe representative experiments. Data represent mean ± SEM., *p
Cimportant regulators of invadopodia formation and invasion,
including NRAS, PI3K, SRC, and ERK (Yamaguchi et al., 2011;
Murphy and Courtneidge, 2011). Interestingly, the activation
status of these pathways was unaffected by changes in GMPR
expression (Figure 6G).
Taken together, our data demonstrate that activity of some,
but not all, small GTPases can be regulated via GMPR-depen-
dent alterations in intracellular GTP pools.
RAC1G12V Supports Melanoma Cell Invasion
Independently of GMPR or Exogenous Guanosine
Among all analyzed small GTPases, the ability of RAC1 to bind
GTP appeared to be the most sensitive to changes in GMPR
levels. A constitutively active form of RAC1, RAC1G12V, has
been shown to induce invasion in several cell systems (Zhuge
and Xu, 2001; Michiels et al., 1995; van Leeuwen et al., 1995),
although RAC1 activation had opposite effects in others (Engers
et al., 2001; Uhlenbrock et al., 2004; de Toledo et al., 2012). Thus,
we were interested in investigating whether the sustained activa-
tion of RAC1 increases invasion of the studied melanoma cells
and, if so, whether or not RAC1G12V-dependent invasion would
be affected by guanylate pool alteration. To this end, SK-Mel-
103 cells were transduced with an empty retroviral vector or a
vector encoding RAC1G12V cDNA. The resulting cell populations
were superinfected with an empty lentiviral vector or a vector
expressing GMPR and tested for invasion in the Matrigel assay.
Overexpression of RAC1G12V (Figure 7A) increased invasion of
SK-Mel-103 cells compared to the ‘‘vector’’ cells (Figure 7B). Su-
perinfection with GMPR cDNA led to a modest decrease in the
invasion of RAC1G12V-melanoma cells, whereas invasion of vec-
tor-melanomacellswasdeeplyaffected, asexpected (Figure7B).
Moreover, unlike control cells, other invasion-associated pheno-
types were affected only minimally in RAC1G12V-melanoma cells
(Figure S6), and invasion of RAC1G12V-cells was not significantly
affected by treatment with 0.4 mM of MPA (Figure 7C).ation and invasion.
R shRNA1 (G1), or GMPR shRNA2 (G2) were probed in western blotting with
dicated cells treated or not with 100 mM of guanosine (‘‘Guanosine’’).
inedwith rhodamine-conjugated phalloidin.Where indicated, cells were grown
g on the gelatin.
f cells with gelatin degradation was determined by counting at least 50 cells.
the area of gelatin degradation.
< 0.05; *p < 0.001 by Student’s t test. See also Figure S4.
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Figure 6. GMPR Regulates Activity of Rho-GTPases
(A) GTP-bound RAC, CDC42, RHOA, RHOC, and NRAS were pulled down from total cell lysates of SK-Mel-103 melanoma cells expressing human GMPR or
empty vector. GTP-bound (active) and total RAC1, CDC42, RHOA, RHOC, and NRAS were detected by immunoblotting.
(B) SK-Mel-103 melanoma cells were treated with the indicated amounts of MPA for 24 hr and tested for proliferation and invasion. Shown are the percentage of
EdU-positive cells and relative invasion index of indicated cells.
(C) GTP amounts were measured by HPLC in SK-Mel-103 cells treated or not with 0.4 mM or 1.0 mM of MPA. Normalized amounts of GTP are shown.
(legend continued on next page)
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Figure 7. RAC1G12V Suppresses GMPR Phenotype
(A) SK-Mel-103 melanoma cells were transduced with an empty retroviral vector or a vector expressing human RAC1G12V cDNA followed by superinfection with
empty lentiviral vector (‘‘V’’) or human GMPR cDNA (‘‘G’’). Four days after the second transduction, total protein extracts from transduced cells were probed in
western blotting with indicated antibodies.
(B) Cells described in (A) were tested for invasion.
(C) Cells described in (A) were treated or not with 0.4 mM of MPA followed by invasion assay.
(D) SK-Mel-28 cells were transduced with empty lentiviral vector or vector expressing human RAC1G12V cDNA followed by superinfection with control shRNA (‘‘Cl
sh’’) or with GMPR shRNA1 (‘‘GMPR sh1’’). Four days after the second infection, total protein extracts from transduced cells were probed in western blotting with
the indicated antibodies.
(E) Cells described in (D) were tested for invasion.
(F) SK-Mel-28 cells expressing vector or RAC1G12V were treated with the indicated amounts of guanosine for 24 hr and tested for invasion.
*p < 0.05 by Student’s t test, compared to control. Data represent mean ± SEM. All panels describe representative experiments. See also Figure S6.To complement these studies, we depleted GMPR levels via
shRNA in vector- or RAC1G12V-expressing SK-Mel-28 cells (Fig-
ure 7D). The Matrigel assay demonstrated that invasion of
RAC1G12V-expressing cells was not increased by depletion of
GMPR (Figure 7E) or by incubation with 100 mM of guanosine
(Figure 7F). Therefore, RAC1 contributes to the invasive pheno-
type of melanoma cells, and constitutive activation of this small
GTPase supersedes the effects of intracellular GTP level
manipulation.(D) Pull-down assays of GTP-bound RAC1, CDC42, RHOA, and RHOC in SK-Me
(E and F) SK-Mel-28 cells expressing control shRNA (Cl), GMPR shRNA1 (G1), or G
not with guanosine (‘‘G’’) for 24 hr (F) were subjected to pull-down assays as de
(G) Whole-cell extracts from the indicated cell lines and treatments were probed
(H)Data representingmean±SEMofquantification ofGTP-boundGTPase to total
*p < 0.05; **p < 0.001 by Student’s t test.
CDISCUSSION
In melanoma, the acquisition of the invasive phenotypes occurs
during the early stages of progression and is considered a critical
event strongly associated with poor prognosis (Balch et al.,
2009). The molecular mechanisms underlying melanoma inva-
sion are still poorly understood. Here, we report the identification
of GMPR as a negative regulator of the invasive melanoma
phenotype. Our data are in agreement with a previous studyl-103 melanoma cells treated or not with 0.4 mM of MPA for 24 hr.
MPR shRNA2 (G2) (E) and SK-Mel-28 cells growing in media supplemented or
scribed above. For all panels, representative images are provided.
with indicated antibodies.
GTPase from three independent experiments asdescribed in (A), (D), (E), and (F).
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establishing an expression signature characteristic of ‘‘invasive’’
versus ‘‘proliferative’’ phenotypes of freshly isolated human
metastatic melanoma cells (Hoek et al., 2006), where GMPR
was among several dozen genes that were underexpressed in
melanoma cells with increased invasion.
The function of GMPR in cellular processes has not been well
characterized. Through gain- and loss-of-expression experi-
ments, we demonstrated that GMPR negatively regulates phe-
notypes associated with invasion (formation of invadopodia,
localized matrix degradation, invasion through Matrigel). Two
independent lines of evidence demonstrate that GMPR sup-
presses invasion via the depletion of GTP pools. First, expres-
sion of the catalytic null GMPRC186A mutant did not affect
melanoma invasion (Figure 2E). Second, supplementation of
culture medium with guanosine restored the GMPR-affected
phenotypes (Figure 2G). Accordingly, the addition of guanosine
increased the endogenous invasive potential of SK-Mel-28,
SK-Mel-103, and SK-Mel-147 cells (Figures 2G and 4E), sug-
gesting that elevated guanosine levels in melanoma patients
may be associated with a more aggressive invasive phenotype
and consequently with less favorable prognosis. The rather
modest increase in the invasion of SK-Mel-103 and SK-Mel-
147 cells was most likely due to the already high basal invasion
potential of these cells.
Recently, an elegant study by Arozarena et al. has implicated
cyclic GMP (cGMP) production in the regulation of invasion of
melanoma cells expressing mutant BRAFV600E (Arozarena
et al., 2011). We did not detect changes in the intracellular
cGMP amounts in cells ectopically expressing GMPR or treated
with mycophenolic acid (Figure S2A), in agreement with a previ-
ous report (Kleinschmidt et al., 1977). Additionally, the cGMP-
dependent regulation of invasion was shown to be specific to
melanoma cells containing mutant BRAFV600E (Arozarena et al.,
2011), whereas manipulation with GMPR levels regulated inva-
sion in cells expressing mutant BRAFV600E (SK-Mel-28) as well
as wild-type BRAF (SK-Mel-103 and SK-Mel-147). Thus,
GMPR appears to control invasion via cGMP-independent
mechanisms. Instead, our data demonstrated that GMPR acts
via finely tuned regulation of RAC1 and, to a lesser extent,
RHOA and RHOC (Figures 6A, 6D, 6E, and 6H).
At the same time,GMPRexpression did not affect the amounts
of GTP-bound CDC42, another member of the same Rho family
of small GTPases, and NRAS, a small GTPase that does not
belong to the Rho family (Figures 6A and 6E). These findings
are not surprising because differential reaction to the same
stimulus has been reported for different members of Rho-
GTPases (Hallett et al., 2003; Noren et al., 2001). For instance,
antimycin A-induced depletion of ATP and GTP pools in porcine
proximal tubule cells resulted in differential suppression of the
activity of RHOA, RAC1, and CDC42 (Hallett et al., 2003).
An antagonistic relationship between RAC1 and RHOA has
been documented in several cell systems (Alberts et al., 2005;
Nimnual et al., 2003; Wildenberg et al., 2006; Wang et al.,
2003), though in our experiments both GTPases were affected
by GTP depletion. One possible explanation for this discrepancy
is that GTP depletion affects RHOA and RAC1 to an extent that
supersedes the inverse relationship between these proteins.
Alternatively, because in a few instances a concordant regulation504 Cell Reports 5, 493–507, October 31, 2013 ª2013 The Authorsof RAC1 and RHOA has been reported (Clerk et al., 2001; Zhu
et al., 2013), this may be the case in our system as well.
What are the mechanisms by which GMPR controls activity of
RAC1, RHOA, or RHOC in studied cells? On one hand, we failed
to detect GMPR-dependent changes in the activation status of
major regulators of invasion that act upstream of theseGTPases,
including NRAS, AKT, ERK, or Src-family proteins. On the other
hand, subtle depletion of total cellular GTP pools by GMPR or
MPA still leaves the remaining GTP pools at concentrations
that are substantially higher than the GTP affinity constants of
studied GTPases (Zhang and Zheng, 1998), arguing against
GMPR-dependent interference with GTP loading of Rho-
GTPases. However, ATP and GTP may not be homogeneously
distributed in the cell. Indeed, using luminescence-based sen-
sors, several recent studies demonstrated temporal and spatial
variation in ATP levels in response to various stimuli (Manfredi
et al., 2002; Imamura et al., 2009; Kennedy et al., 1999). Addition-
ally, it has been reported that ectopic expression of a salvage
ATP biosynthesis enzyme adenylate kinase 1 (AK1) increased
cell motility and spreading to the highest degree when it was
tagged to the focal contacts compared to membrane or cytosol
(van Horssen et al., 2009). Unlike ATP, presently there are no
sensors for the direct measurement of GTP levels in a live cell.
However, because GTP, like ATP, is one of the most common
allosteric modulators of protein functions, it is conceivable that
GTP distribution in the cell follows a similar pattern. Therefore,
GTP depletionmay be evenly distributed throughout the gradient
of GTP amounts and affect GTP binding of a GTPase at the areas
where localized GTP concentration is already low. Alternatively,
the degree of GTP depletion may vary in different compartments
of a cell and thus may be more prominent in localized areas (i.e.,
at the invadopodia sites) where it leads to inhibition of GTP
loading. Finally, we cannot rule out the existence of yet-uniden-
tified mechanisms of GMPR-dependent regulation of Rho-
GTPase activity.
In summary, we have identified GMPR as a suppressor of
melanoma invasion, which is already downregulated at the early
invasive stages of melanoma progression and whose activity
inhibits melanoma cell invasion by depleting intracellular GTP
pools. Moreover, our data provide experimental evidence that
melanoma cells utilize small alterations of intracellular GTP pools
as an important regulatory mechanism of the activity of several
small Rho-GTPases involved in cell invasion.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
Melanoma cell lines were obtained from Memorial Sloan Kettering Cancer
Center and cultured in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal calf serum, 2 mM glutamine, and penicillin-streptomycin anti-
biotics. Populations of normal human melanocytes were purchased from
Invitrogen and maintained in Medium 254 (Invitrogen) supplemented with hu-
man melanocyte growth supplement (Invitrogen). Mycophenolic acid, guano-
sine, and Hoechst were purchased from Sigma-Aldrich.
Animals were maintained and all experiments were conducted according to
a protocol approved by the Institute Animal Care and Use Committee at Ros-
well Park Cancer Institute. The facility has been certified by the American As-
sociation for Accreditation of Laboratory Animal Care in accordance with the
current regulations and standards of the U.S. Department of Agriculture and
the U.S. Department of Health and Human Services.
Immunoblotting
Membranes were developed with alkaline phosphatase-conjugated second-
ary antibodies and signals were visualized using the Alpha-Innotech
FluorChem HD2 imaging system (Alpha Innotech) and quantified using
ImageQuant software (GE Healthcare Life Sciences). For a list of antibodies
used in this study, see Supplemental Experimental Procedures.
Immunohistochemistry
Formalin-fixed and paraffin-embedded human melanocytic cells and cuta-
neous and metastatic melanoma tissue were processed at the Pathology
Core Facility (Roswell Park Cancer Institute). Positive and negative control
slides were supplied by the Pathology Core Facility and were included with
every immunochemistry run. For IMPDH2 antibodies (Atlas Antibodies,
HPA001400) and GMPR antibodies (Sigma-Aldrich, HPA021476), the Novo-
castra PowerVision kit was used for visualization, followed by Fast Red
(Thermo Scientific). The slides were manually counterstained with hematoxy-
lin. Human tissue specimens were scored for intensity of staining by a board-
certified pathologist. Samples of cultured melanocytic cells were scored
only for intensity. For more information, see Supplemental Experimental
Procedures.
Statistical Analysis
Student’s t test was used to assess the significance of differences in data
obtained in cell-based experiments or the tumor xenograft growth assay.
The data obtained in the tumor latency assay were analyzed using the log-
rank test. Xenograft invasion was analyzed with the Fisher’s exact test.
Plasmids and Infection
Lentiviral and retroviral infection protocols were described previously
(Mannava et al., 2008). All infected cells were briefly selected for resistance
to respective selectable markers and subjected to the assays. For a list of
plasmid used in this study, see Supplemental Experimental Procedures.
Proliferation Assay
Melanoma cells were plated in 96-well plates at 30% confluence 1 day
before the assay. Cells were tested for EdU incorporation using the Click-iT
EdU Cell Proliferation Assays (Invitrogen) following themanufacturer’s instruc-
tions. The proportion of EdU-positive cells was determined by counting at least
100 cells under a fluorescent microscope.
Matrigel-Based Invasion Assay
The invasion assay was performed using the BioCoat Matrigel invasion
chambers (BD Biosciences) according to the manufacturer’s instructions,
with some modifications. For details, see Supplemental Experimental
Procedures.
Combined Gelatin Degradation Assay
Prewashed coverslips (see Supplemental Experimental Procedures) were
coated with warm Oregon green 488-conjugated gelatin (Invitrogen) at
0.2 mg/ml in 2% sucrose/PBS, followed by crosslinking with ice-cold glutaral-
dehyde 0.5% in PBS, incubation with sodium borohydride (5 mg/ml), and ster-
ilization with 70% ethanol. Coverslips were quenched with serum-free media
for 1 hr at 37C. Melanoma cells (7.5 3 104) were seeded on the coverslips,
and after 16 hr incubation at 37C they were fixed in 4% paraformaldehyde
in PBS and stained with rhodamine-conjugated phalloidin (Invitrogen). Cover-
slips were mounted onto glass slides with aqua-mount media (Polysciences).
Invadopodia were identified as b-actin puncta colocalizingwith areas of gelatin
degradation. The area of gelatin degradation was quantified using ImageJ
(NIH) software.
GTP-Bound GTPase Pull-Down Assay
The assay was performed using the RHOA/RHOC/RAC1/CDC42 Activation
Assay Combo kit (Cell Biolabs) according to the manufacturer’s recommenda-
tions. For details, see Supplemental Experimental Procedures. Samples were
resolved on polyacrylamide gels along with total lysates as control and visual-
ized as described above.CQuantitative Real-Time PCR
Total cellular RNAwas isolated using the RNeasyMini Kit (QIAGEN). cDNAwas
prepared using cDNA reverse-transcription kit (Invitrogen). Quantitative RT-
PCR was performed on 7900HT Fast Real-Time PCR System (Applied Bio-
systems) using TaqMan Universal Master Mix II (Applied Biosystems) and
probes specific for human b-actin and human GMPR genes. PCR data were
analyzed using sequence detection software 2.4 (Applied Biosystems).
Nucleotide Quantification
Cells were harvested by trypsinization, extracted with 0.4 N perchloric acid,
and neutralized. NTPs were separated and quantified using a strong anion ex-
change column (Whatman) with a gradient HPLC system (Waters) equipped
with a photodiode array detector and controlled by Millennium 2010 software.
Nucleotides were eluted with 0.005M ammonium phosphate (pH 2.8) for 5min
followed by a linear gradient to 0.75 M ammonium phosphate (pH 3.7) over
60 min. Nucleotides were identified based on their UV absorbance spectrum
and quantified at either 254 or 281 nm by comparison to the absorbance of
a known amount of authentic standard.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.09.015.
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